Genetics Institute sales and marketing update

GENIZ posted $9 milllion in sales of its bulk Factor VIII in the third quarter ended Aug. 31. Royalties from sales of erythropoietin (EPO) totalled $6.7 million in the quarter versus $7.3 million in the quarter last year. GENIZ attributed the decrease to reduced royalty rates from its EPO licensees, Chugai Pharmaceuticals Inc. in Japan and Boehringer Mannheim GmbH in Europe. ...